VSTM250117C1000
- 3.90
- 0.000.00%
Verastem Newsroom
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $16
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $20
Verastem Is Maintained at Outperform by RBC Capital
Verastem Price Target Raised to $16.00/Share From $13.00 by RBC Capital
Verastem Analyst Ratings
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $16
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $20
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $20
B.Riley Financial Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Citi Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $7
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
Verastem Is Maintained at Outperform by Mizuho
Verastem Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Verastem Analyst Ratings
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $9
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Verastem's Promising Drug Combination for LGSOC: Analyst Recommends Buy Rating